# Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy

> **NCT05975463** · PHASE2 · NOT_YET_RECRUITING · sponsor: **HuiKai Li** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** HAIC
- **DRUG:** Adebrelimab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05975463
- **Lead sponsor:** HuiKai Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09-15
- **Primary completion:** 2025-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05975463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05975463, "Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05975463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*